| Previous Close | 1.23 |
| Open | 1.25 |
| Day High | 1.32 |
| Day Low | 1.25 |
| 52-Week High | 2.73 |
| 52-Week Low | 0.9 |
| Volume | 4.54M |
| Average Volume | 7.26M |
| Market Cap | 428.4M |
| PE | -5.27 |
| EPS | -0.24 |
| Moving Average 50 Days | 1.52 |
| Moving Average 200 Days | 1.53 |
| Change | 0.04 |
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa
GlobeNewswire Inc.
Mar 02, 2026 12:02 PM GMT
Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and patientsTopline Phase 3 data expected in 1Q 2027, advanci
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results
GlobeNewswire Inc.
Feb 18, 2026 12:02 PM GMT
MALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
GlobeNewswire Inc.
Feb 09, 2026 12:02 PM GMT
MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financi